Aspira Women's Health Inc.
Close on Oct 19, 2026
- Market cap
- $9.91M
- P/E (TTM)
- –
- Dividend yield
- –
About Aspira Women's Health
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Aspira Women’s Health Inc. develops and commercializes diagnostic tests focused on women's gynecologic health. The company specializes in the risk assessment and differential diagnosis of gynecologic diseases, primarily ovarian cancer and conditions such as endometriosis and pelvic masses. Its commercial offerings and pipeline include diagnostic solutions such as Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, and OVAinform, as well as the Aspira Synergy platform. The company provides laboratory-developed tests through its dedicated laboratory facility, Aspira Labs.
The company operates within the United States, providing diagnostic products and clinical laboratory services to healthcare providers and patients. Aspira Women's Health maintains operating facilities in Austin, Texas, and Shelton, Connecticut. Its corporate headquarters and principal executive offices are situated in Austin, Texas.
Summary of the business section of Aspira Women's Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aspira Women's Health Inc.
- Headquarters
- Austin, TX
- Address
- 12117 Bee Caves Road Building Three, Suite 100 78738
- Phone
- (512) 519-0400
- Employees
- 36, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, Boston, Massachusetts
Stock & identifiers
- Ticker
- AWHL
- Exchange
- OTC
- IPO date
- Oct 2, 2000
- Shares outstanding
- 47M, Aug 12, 2026
- Public float
- $4.67M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, May 15, 2023; 1-for-15 reverse, May 12, 2023; 1-for-10 reverse, Mar 4, 2008
- SEC CIK
- 926617
- CUSIP
- 04537Y208
- ISIN
- US04537Y2081
- EIN
- 33-0595156
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nicole Sandford | Chief Executive Officer, Director | 83,668 |
| John Strahley | Chief Financial Officer | – |
| Brian Hungerford | Chief Financial Officer | – |
| Michael William Buhle | Chief Executive Officer | – |
| James C. Crawford | Vice President of Finance | – |
| Sandra Milligan | Interim CEO | 13,644 |
| John A. Kallassy | Interim CFO | – |
| Jeffrey k. cohen | Director | 457,028 |
| John D. Fraser | Director | 854,162 |
| Cynthia D. Hundorfean | Director | – |
| Jane Pine Wood | Director | – |
| Winfred Parnell | Director | 71,209 |
| Ellen Beausang | Director | 6,458 |
| Ellen O'Connor Vos | Director | 73,989 |
| John Phillip Ragard | Director | 134,734 |
| Stefanie L. Cavanaugh | Director | 78,726 |
| Jannie Prestridge Herchuk | Director | 82,502 |
| Celeste Rachelle Fralick | Director | 55,665 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Michael Buhle | $419.93K | $575.88K | $141.05K | $1 | – |
| FY2025 Nicole Sandford | $0 | $0 | $141.05K | $1 | – |
| FY2025 Sandra Milligan | $80.51K | $79.71K | $141.05K | $1 | – |
| FY2024 Michael Buhle | $0 | $0 | $173.55K | $1 | – |
| FY2024 Nicole Sandford | $1.24M | $834.85K | $173.55K | $1 | – |
| FY2024 Sandra Milligan | $358.43K | $281.76K | $173.55K | $1 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 36 full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings